When will Regeneron report Q1 earnings?

Regeneron will report Q1 2026 earnings on Wednesday.

Which key products are analysts focusing on?

Analysts are focusing on Eylea (for wet AMD) and Dupixent (for asthma and atopic dermatitis).

Has Regeneron issued any forward guidance?

Regeneron has not yet issued guidance for Q2 or full-year 2026.

How could the report affect REGN stock?

REGN stock could see significant movement based on Q1 results and management guidance, as any surprises may drive volatility.

Regeneron (REGN) Q1 2026 Earnings Preview: What to Expect

Regeneron Pharmaceuticals (NASDAQ:REGN) will report Q1 2026 earnings on Wednesday morning. Analysts focus on sales of key products and any forward guidance.

Biotech company Regeneron Pharmaceuticals (NASDAQ:REGN) is set to report its first-quarter 2026 earnings on Wednesday morning. Investors are keenly awaiting revenue and profit figures, with particular attention on the performance of flagship drugs Eylea and Dupixent. The company has not pre-announced results, but analysts expect growth driven by core product sales.

Key Financial Metrics

Results have not been released yet. The table will be updated after the official announcement.

Metric	Q1 2026	Q1 2025	Change
Revenue	TBD	TBD	-
Net Income	TBD	TBD	-
EPS	TBD	TBD	-

Key Takeaways from the Report

Details will be added after the earnings release. Management is expected to discuss Eylea (for wet age-related macular degeneration) and Dupixent (for asthma and atopic dermatitis), as well as pipeline progress.

Forward Guidance

No guidance has been issued for Q2 or full-year 2026. Any updates will be a key focus for analysts.

Stock Impact

Regeneron's stock (REGN) could see significant movement based on the results and management's outlook. Positive or negative surprises in revenue or guidance may drive volatility.

What This Means for Investors

Investors are watching Regeneron's Q1 results to gauge the health of its core business and growth trajectory. It is advisable to review the official release and management commentary on product demand and market expansion.